arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be
Company profile
Ticker
RCUS
Exchange
Website
CEO
Terry J. Rosen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Arcus Biosciences Australia PTY LTD ...
RCUS stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
21 Feb 24
S-8
Registration of securities for employees
21 Feb 24
10-K
2023 FY
Annual report
21 Feb 24
8-K
Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update
21 Feb 24
8-K
Entry into a Material Definitive Agreement
30 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update
7 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
8-K
Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update
7 Aug 23
8-K
Entry into a Material Definitive Agreement
28 Jun 23
Latest ownership filings
4
Jennifer Jarrett
29 Mar 24
144
Notice of proposed sale of securities
27 Mar 24
4
Jennifer Jarrett
20 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Jennifer Jarrett
28 Feb 24
4
Juan C. Jaen
28 Feb 24
4/A
II Robert C. Goeltz
23 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G
FMR LLC
9 Feb 24
3
Johanna Mercier
7 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 187.00 mm | 187.00 mm | 187.00 mm | 187.00 mm | 187.00 mm | 187.00 mm |
Cash burn (monthly) | 15.33 mm | 2.83 mm | 26.67 mm | 26.92 mm | 21.00 mm | 24.00 mm |
Cash used (since last report) | 104.18 mm | 19.25 mm | 181.19 mm | 182.89 mm | 142.69 mm | 163.07 mm |
Cash remaining | 82.82 mm | 167.75 mm | 5.81 mm | 4.11 mm | 44.31 mm | 23.93 mm |
Runway (months of cash) | 5.4 | 59.2 | 0.2 | 0.2 | 2.1 | 1.0 |
Institutional ownership, Q3 2023
95.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 192 |
Opened positions | 32 |
Closed positions | 24 |
Increased positions | 52 |
Reduced positions | 72 |
13F shares | Current |
---|---|
Total value | 932.95 bn |
Total shares | 86.79 mm |
Total puts | 607.70 k |
Total calls | 592.00 k |
Total put/call ratio | 1.0 |
Largest owners | Shares | Value |
---|---|---|
GILD Gilead Sciences | 25.59 mm | $514.30 mm |
BLK Blackrock | 9.62 mm | $172.66 bn |
FMR | 4.78 mm | $85.80 bn |
Vanguard | 4.49 mm | $80.66 bn |
STT State Street | 4.20 mm | $75.39 bn |
GV 2016 | 2.56 mm | $0.00 |
Biotechnology Value Fund L P | 2.30 mm | $0.00 |
Foresite Capital Fund III | 2.03 mm | $21.85 mm |
Octagon Capital Advisors | 1.97 mm | $35.33 bn |
Invus Financial Advisors | 1.61 mm | $28.94 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Jarrett Jennifer | Common Stock | Sell | Dispose S | No | Yes | 17.55 | 11,551 | 202.72 k | 215,253 |
18 Mar 24 | Jarrett Jennifer | Common Stock | Sell | Dispose S | No | No | 18.62 | 1,296 | 24.13 k | 226,804 |
18 Mar 24 | Jarrett Jennifer | Common Stock | Sell | Dispose S | No | No | 17.84 | 12,153 | 216.81 k | 228,100 |
27 Feb 24 | Jarrett Jennifer | Common Stock | Sell | Dispose S | No | Yes | 20.11 | 34,070 | 685.15 k | 240,253 |
27 Feb 24 | Jaen Juan C. | Common Stock | Sell | Dispose S | Yes | Yes | 20.1 | 23,132 | 464.95 k | 1,188,233 |
26 Feb 24 | Jarrett Jennifer | Common Stock | Sell | Dispose S | No | Yes | 20.07 | 24,555 | 492.82 k | 274,323 |
26 Feb 24 | Jaen Juan C. | Common Stock | Sell | Dispose S | Yes | Yes | 20.06 | 3,900 | 78.23 k | 1,211,365 |
29 Jan 24 | Gilead Sciences | Common Stock | Buy | Acquire P | No | No | 21 | 15,238,095 | 320.00 mm | 30,061,124 |
News
Navigating 5 Analyst Ratings For Arcus Biosciences
25 Mar 24
Truist Securities Reiterates Buy on Arcus Biosciences, Maintains $50 Price Target
25 Mar 24
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
22 Feb 24
Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $30 Price Target
22 Feb 24
Recap: Arcus Biosciences Q4 Earnings
21 Feb 24
Press releases
Arcus Biosciences Announces New Employment Inducement Grants
9 Apr 24
Arcus Biosciences Announces New Employment Inducement Grants
26 Mar 24
Arcus Biosciences Announces New Employment Inducement Grants
11 Mar 24
Arcus Biosciences Announces New Employment Inducement Grants
27 Feb 24
Arcus Biosciences Announces New Employment Inducement Grants
9 Feb 24